*
Scoring Key: 5=Strongly Agree 4= Somewhat agree 3=Neither agree nor disagree 2= Somewhat disagree 1=Strongly disagree NA=Not applicable
54321NA
The skills learned in this CME course enhanced my professional competence.
The skills learned in this CME course will be applied in the treatment of my patients
*
5 = High level of competence 4 = Moderately high level of competence 3 = Average level of competence 2 = Low level of competence 1 = No level of competence
54321
Implement therapeutic strategies when treating hematologic malignancies.
Provide an update of new molecular and immunological treatments being developed for these diseases.
Discuss and analyze the rationale for new targeted diagnostic and therapeutic strategies for lymphoma, myeloma and leukemia.
Assessing your ability to review the role and timing of hematopoietic cell transplantation and potential combinations of immunotherapeutic treatment options.
*
Scoring key: 5=Very effective, 4= Effective, 3= Somewhat effective, 2= Slightly effective, 1= Completely Ineffective, N/A= Not Applicable/Did Not Attend
54321Not Applicable
Landscape of AML in 2020 - Marty Tallman, M.D.
Risk-Adapted Treatment Strategies for AML - Eytan M. Stein, M.D.
Allogeneic Transplants for AML in 2020 - Robert Soiffer, M.D.
Landscape of ALL in 2020 - Nitin Jain, M.D.
MRD in ALL - Wendy Stock, M.D.
Allogeneic Transplants for ALL in 2020 - Robert Soiffer, M.D.
Landscape of NHL in 2020 - Anas Younes, M.D.
Landscape of Hodgkin’s Disease in 2020 - Anas Younes, M.D.
Landscape of Multiple Myeloma in 2020 - Paul G. Richardson, M.D.
MRD in Multiple Myeloma (Recorded Video Lecture) - Ola Landgren, M.D., Ph.D.
Targeted Therapies in Multiple Myeloma - Adam D. Cohen, M.D.
Wilms’ Tumor Antigen 1 in Multiple Myeloma - Guenther Koehne, M.D., Ph.D.
*
*
*
*
*
*
*
*